Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-03-26
2011-12-06
Sullivan, Peter O (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S535000, C514S609000, C564S027000, C564S104000, C560S013000
Reexamination Certificate
active
08071650
ABSTRACT:
The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.
REFERENCES:
patent: 3117994 (1964-01-01), McKay et al.
patent: 3546344 (1970-12-01), Martin et al.
patent: 4460602 (1984-07-01), Buckwalter et al.
patent: 5403868 (1995-04-01), Reid et al.
patent: 5780483 (1998-07-01), Widdowson et al.
patent: 6057451 (2000-05-01), Crute et al.
patent: 6288091 (2001-09-01), Crute et al.
patent: 2003/0203944 (2003-10-01), Suh et al.
patent: 2003/0212140 (2003-11-01), Suh et al.
patent: 0 405 233 (1993-10-01), None
patent: 0 462 933 (1994-06-01), None
patent: 0 528 146 (1996-02-01), None
patent: 1031165 (1966-05-01), None
patent: 2 168 975 (1986-07-01), None
patent: 2 206 347 (1989-01-01), None
patent: 11-35545 (1999-02-01), None
patent: WO 95/13387 (1995-05-01), None
patent: WO 95/21886 (1995-08-01), None
patent: WO 98/05779 (1998-02-01), None
patent: WO 98/18914 (1998-05-01), None
patent: WO 99/00115 (1999-01-01), None
patent: WO 99/37676 (1999-07-01), None
patent: WO 99/43801 (1999-09-01), None
patent: WO 00/50387 (2000-08-01), None
patent: WO 02/08221 (2002-01-01), None
patent: WO 02/072536 (2002-09-01), None
patent: WO 02/076946 (2002-10-01), None
patent: WO 02/090326 (2002-11-01), None
patent: WO 03/014064 (2003-02-01), None
Domenico Spina et al., Pharmacology of airway irritability, pp. 264-272.
Jeewoo Lee et al.,Bioorganic&Medicinal Chemistry, 9 (2001) 19-32.
Yun Wang et al.,Molecular Pharmacology, vol. 62. No. 4, pp. 947-956 (2002).
Jung Wha Yoon et al.,Bioorganic&Medicinal Chemistry Letters, 4 pp (Article in Press).
Hyeung-geun Park et al.,Bioorganic&Medicinal Chemistry Letters13 (2003) pp. 601-604.
Hyeung-geun Park et al.,Bioorganic&Medicinal Chemistry Letters13 (2003) pp. 197-200.
Oh et al., 1996, J. Neurosci. 16 pp. 1659-1667.
Wrigglesworth et al., “Analogues of Capsaicin with Agonist Activity as Novel Analgesic Agents: Structure-Activity Studies. 4. Potent, Orally Active Analgesics,” J. Med Chem. 1996, 39 4942-4951.
McKay et al., “Bacteriostats. VI.1aBacteriostatic Activities of Some Substituted Guanidines1b,” Bacteriostats. VI, Sep. 1963, 587-595.
“Controlling Pain in the 21stCentury,” Report on the Society for Medicines Research Meeting Held at Charing Cross and Westminster Medical School, London, Jul. 10, 1997.
Modulation of Capsaicin-Induced Calcium Uptake into Primary Cultured Rat Dorsal Root Ganglion Sensory Neurons and Characterization of Capsaicin-Hydrolyzing Enzyme Purified from Rat Liver, Feb. 1996.
Christopher S. J. Walpole et al., “The Discovery of Capsazepine, the First Competitive Antagonist of the Sensory Neuron Excitants Capsaicin and Resiniferatoxin,” J. Med. Chem., vol. 37, No. 13, Jun. 24, 1994, pp. 1942-1954.
Gilles Klopman et al., “Quantitative structure-agonist activity relationship of capsaicin analogues,” Journal of Computer-Aided Molecular Design, vol. 9, No. 3, (1995) pp. 283-294.
M. Hosseini et al., “Using Artificial Neural Networks to Classify the Activity of Capsaicin and its Analogues,” J. Chem. Inf. Comput. Sci., vol. 37, No. 6, Nov. 1997, pp. 1129-1137.
Edward K. Dziadulewicz et al., “1-(2-Nitrophenyl)thiosemicarbazides: A Novel Class of Potent, Orally Active Non-Peptide Antagonist for the Bradykinin B2Receptor,” J. Med. Chem. vol. 43, No. 5, 3/9/200 pp. 769-771.
John F. Olin et al., “The Action of the Halogen Hydrins and of Ethylene Oxide on the Thioureas,” Journal of the American Chemical Society, vol. 52, No. 8, Aug. 1930, pp. 3323-3327.
Charles Larsen et al., “Thermal Fragmentations VI. The Preparation of Aryl N-Monoalkydithiocarbamates and Their Behaviour upon Heating,” ACTA Chemica Scandinavica, vol. 27, No. 6, Jun. 1973, pp. 2001-2012.
Zhen-Chu Chen et al., “Polyvalent Iodine in Synthesis. 2. A New Method for the Preparation of Aryl Esters of Dithiocarbamic Acids,” Journal of Organic Chemistry, vol. 52, No. 18, Sep. 4, 1987, pp. 4117-4118.
Eugene Lieber et al., “Reaction of 5-Amino-1,2,3,4-Thiatriazole with Benzylamine,” Journal of Organic Chemistry, vol. 22. No. 930, Sep. 1957, pp. 1054-1056.
J. Bourdais et al., “Polycyclic Azines. Ill. Synthesis of 3-Aminoimidazol[1,5-α]pyridine Derivatives by Cyclodesulphurization of N′-Substituted -N-(2-Pyridylmethyl)thioureas with Dicyclohexylcarbodiimide (2,3),” Journal of Heterocyclic Chemistry, vol. 17, No. 5, May 1980, pp. 555-558.
Walter Ried et al., “2-Imino-1, 3-thiezetidine aus Thioharnstoffen mit intramolekularer Wasserstoffbrücke,” Chemische Berichte, vol. 111, No. 1, Jan. 1978, pp. 143-154.
Szallasi and Blumberg, 1999, Pharm. Rev. 51, pp. 159-211.
Wrigglesworth and Walpole, 1998, Drugs of the Future 23, pp. 531-538.
Wood et al., 1998, J. Neurosci. 8 pp. 3208-3220.
Caterina et al., 1997, Nature 389, pp. 816-824.
Tominaga et al., 1998, Neuron 21, pp. 531-543.
Caterina et al., 2000, Science 288, pp. 306-313.
Davis et al., 2000, Nature 405, pp. 183-187.
Hwang et al., 2000, PNAS 97, pp. 6155-6160.
Zygmunt et al, 2000, Trends Pharmacol. Sci, 21, pp. 43-44.
Ren et al., 2000, Dig. Dis. Sci. 45, pp. 830-836.
Perkins and Campbell, 1992, Br. J. Pharmacol. 107, pp. 329-333.
Kwak et al., 1998, Neurosci. 86, pp. 619-626.
Santos and Calixto, 1997, Neurosci. Lett 235, pp. 73-76.
McDonnell et al., 2002, Bioorg. Med. Chem. Lett. 12, pp. 1189-1192.
Lee et al., 2002, Bioorg. Med. Chem. Lett. 10, pp. 1171-1179.
Lee et al., 2001, Bioorg. Med. Chem. Lett. 9, pp. 1713-1720.
Wahl et al., 2001, Mol. Pharmacol. 59, pp. 9-15.
Chem Abstract Online printout of JP 11-35545, 1999, m=221070-38-3.
Jeewoo Lee et al., “3-Acyloxy-2-phenalkylpropyl Amides and Esters of Homovanillic Acid as Novel Vanilloid Receptor Agonists,” Bioorganic & Medicinal Chemistry Letters 9 (1999) 2909-2914.
K. D. Janda et al., “Antibody Catalysis of Bimolecular Amide Formation,” J. Am. Chem. Soc. 1988, 110, 4835-4837.
Accession No. (AN) 2004:429173 CHEMCATS, Jan. 1, 2004.
Accession No. (AN) 2003:2480724 CHEMCATS, Nov. 12, 2004.
Choi Jin Kyu
Jeong Yeon Su
Joo Yung Hyup
Kim Hee Doo
Kim Jin Kwan
O Sullivan Peter
Pacific Corporation
Rothwell Figg Ernst & Manbeck P.C.
LandOfFree
Thiourea derivatives and the pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiourea derivatives and the pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiourea derivatives and the pharmaceutical compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4314715